All News
Gout Imaging in Care
Gout is all about the crystals and the consequences of the disease are due to the inflammation they cause.
Read Article
20 yr. Tx trends in 6583 #SSc pts. 2005 to 2025 endothelin receptor antagonists & prostanoids/prostacyclins from 3% to 28%. CCB & PDE-5 inh stable. CTX shifted to mycophenolate, RTX, & nintedanib. Steriods decr from 50% to 18% https://t.co/nrm1Ov285f https://t.co/ftLn3bGH72
Dr. John Cush RheumNow ( View Tweet)
Registration is now open!
Join Dr. Jack Cush as he moderates an expert discussion with Dr. Nicola Dalbeth, Dr. John Fitzgerald, and Dr. Sarah Tedeschi on the evolving role of imaging in gout.
Topics include:
🔹 Ultrasound
🔹 Dual-energy CT (DECT)
🔹 Crystal identification
🔹 https://t.co/iOOAAAEneX
Dr. John Cush RheumNow ( View Tweet)
True or False: Extreme weight loss methods such as bariatric surgery and ketogenic diets may trigger gouty attacks, unlike GLP-1 agonist-induced weight loss.
Test your RheumIQ in this week's quiz at https://t.co/8BuwihOvfE.
Dr. John Cush RheumNow ( View Tweet)
EMD Serono Announces FDA Breakthrough Therapy Designation for Enpatoran (TLR 7/8 inhibitors) for use in Cutaneous Lupus; based on the results from the Phase 2 WILLOW study https://t.co/TNM4whC0Qk https://t.co/70Cibg1gkW
Dr. John Cush RheumNow ( View Tweet)
FDA - a 120Year History Protecting Americans. Nice overview.
- Began 1906 (as Bureau of Chemistry) w/ Pure Food & Drugs Act
- 1930 changed to Food and Drug Administration
- 1938 Food, Drug, and Cosmetics Act
- 1960s denied thalidomide approval https://t.co/3Ey98M9sxw My https://t.co/JS36EfJ19k
Dr. John Cush RheumNow ( View Tweet)
DMARD Efficacy in RA-ILD
A network meta-analysis in the Journal of Autoimmunity reviews the pharmacologic options for rheumatoid arthritis–associated interstitial lung disease (RA-ILD). RA-ILD guidelines were recently presented by ERS/EULAR, but these were mainly conditional,
Dr. John Cush RheumNow ( View Tweet)
New research shows synovial lining enriched in macrophages expressing SPP1 (encoding osteopontin) in proximity to fibroblasts and fibrin deposits. SPP1+ macrophages degrade fibrin & promote fibroblast proliferation that deposit collagen & does the damage, joint remodeling. A new https://t.co/yFxwAYFPPb
Dr. John Cush RheumNow ( View Tweet)
"People wish their enemies dead—but I do not; I say give them the gout, give them the stone!" — Mary Wortley Montagu
Dr. John Cush RheumNow ( View Tweet)
Uric Acid: Is Lower Better?
There is good evidence that a serum urate less than 6 mg/dL is required to meaningfully reduce urate crystal and gout flare burden, but is even lower better and are there any tradeoffs?
https://t.co/W5FsDC5FG0 https://t.co/7mRgkg00uV
Dr. John Cush RheumNow ( View Tweet)
Updated Algorithm for the Management of Restless Legs Syndrome
Diagnose: chronic vs intermittent RLS (no need for polysomnography)
Test Iron levels (& Rx if)
Consider: remove exacerbators; walking/massage/heat; carbidopa/ levodopa; pramipexole or ropinirole; low potency opioids; https://t.co/XdzIipw1X8
Dr. John Cush RheumNow ( View Tweet)
True or False: EULAR recommends glucocorticoids alone, without additional agents, for remission induction in life-threatening ANCA-associated vasculitis.
Did you get it right? Take this week's RheumIQ quiz at https://t.co/TBlB4pmnKa. https://t.co/4IsId6lJ4Y
Dr. John Cush RheumNow ( View Tweet)
True or False: There is an available antidote for colchicine overdose. Check your answer in this week's RheumIQ at https://t.co/TBlB4pmnKa. https://t.co/RgJ4xEAuZA
Dr. John Cush RheumNow ( View Tweet)
The mortality gap in gout has not improved in 20 years – CV disease is the leading cause of death (2-fold increase).
For more gout content, follow our Gout: More than Flares campaign at https://t.co/xnBVBN5IXZ, https://t.co/c12GmMaatt
Dr. John Cush RheumNow ( View Tweet)
QD Clinic: Cellulitis Paradoxes
Dr. Richard Conway, Dublin, discusses a case of cellulitis and gout. Presented as part of RheumNow's "Gout: More than Flares" campaign during the month of July 2026.
https://t.co/ZeYyISJrrE https://t.co/2Ih4QRa7FK
Dr. John Cush RheumNow ( View Tweet)
FDA Delays Gout Drug NASP with Complete Response Letter
On June 26, 2026, SOBI received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) that will delay a decision on NASP, pending the company's answer to questions regarding the drugs https://t.co/NmPbWmYd0p
Dr. John Cush RheumNow ( View Tweet)
Non-gout drugs that may lower uric acid – losartan, amlodipine, ACE inhibitors, fenofibrate, atorvastatin, leflunomide, vitamin C, estrogen, and high-dose ASA.
For more gout content, follow our Gout: More than Flares campaign at https://t.co/xnBVBN5IXZ, https://t.co/vmNvqojAcS
Dr. John Cush RheumNow ( View Tweet)
Problems with treatment adherence in the management of gout
Compared to common medical conditions such as hypertension, type 2 diabetes, hyperlipidemia or osteoporosis, where the reported drug adherence rates are between 50% to 70%, the drug adherence for gout is 37%. This https://t.co/OoLh0HUUH2
Dr. John Cush RheumNow ( View Tweet)
🎥 In this RheumNow Therapeutic Update, Dr. Nicola Dalbeth reviews the latest evidence on the Outcomes of Tophaceous Gout and what every rheumatologist should know.
Watch now: https://t.co/KQmkdziLF5
#Gout #Rheumatology #MedEd #SystemicBurdenOfGout https://t.co/h8LhE5XW00
Dr. John Cush RheumNow ( View Tweet)
Netherlands pragmatic open-label RCT from 8 rheum centres tested T2T vs Sx Rx in 308 Gout pts starting ULT (87% male; 66 yrs). Remission (no flares & pain < 2) betw 18-24 mos was more in T2T pts (39% vs 24%; p=0.02), but more AE w/ Sx driven Rx (53 vs 42%) https://t.co/5g2dY5y900
Dr. John Cush RheumNow ( View Tweet)
